|Dr. Richard John Lipscombe M.A., MA (Oxford), Ph.D., Ph.D., (London)||Co-Founder, MD & Director||442k||N/A||N/A|
|Ms. Jacqueline Gray||Chief Financial Officer||261.95k||N/A||N/A|
|Mr. John Chuck Morrison||Head of Bus. Devel.||N/A||N/A||N/A|
|Dr. Scott Bringans||Head of Research||N/A||N/A||N/A|
|Dr. Pearl Tan||Head of Logistics||N/A||N/A||N/A|
|Mr. Vikesh Malik||Chief Commercialisation Officer||N/A||N/A||N/A|
|Dr. Kirsten Peters||Head of Clinical Studies||N/A||N/A||N/A|
|Ms. Karen Teresa Logan ACIS, B.Com., BCom, DipAppCorpGov, F Fin, FCIS, FC||Company Sec.||N/A||N/A||N/A|
Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research. The company was founded in 2001 and is based in Perth, Australia.
Proteomics International Laboratories Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.